J&J's hep C drug gets German thumbs up; Ex-Sanofi chemist admits to stealing trade secrets;

@FiercePharma: 2004 J&J memo asked reps to "flood clinics with Risperdal stuff" to boost off-label scripts for kids, TX says--Bloomberg. Story | Follow @FiercePharma

> Germany's drug-review panel concluded that Johnson & Johnson's ($JNJ) hepatitis C drug Incivo beats existing drugs at treating the disease, a key step toward price-setting under the country's new system. News

> A former Sanofi ($SNY) chemist pleaded guilty to stealing trade secrets and putting them up for sale in China, prosecutors said. Item

> Bosnia's leading drugmaker, Bosnalijek, predicts it will double profits this year, on top of a 42% increase in profits for 2011. Story

> XOMA ($XOMA) said it acquired U.S. rights to Servier's Aceon brand of blood-pressure products. News

> Savient Pharmaceuticals ($SVNT) has tapped a former SVP at Bristol-Myers Squibb ($BMY), David Veitch, as its new European president. Article

> Zacks maintained its "outperform" recommendation on Celgene ($CELG) after the company released "impressive" preliminary results from the fourth quarter and full year 2011. Item

> Deutsche Bank raised its price targets on Eli Lilly ($LLY) and Pfizer ($PFE), pegging Lilly at $40 and Pfizer at $23, an increase of $2 in each case. Report

Biotech News

@FierceBiotech: Quintiles is pumping $4.6M into UK's Oxford Cancer Biomarkers as part of the CRO's push in personalized medicine. Article | Follow @FierceBiotech

@JohnCFierce: R&D taking a hit in Takeda layoffs, Bloomberg reports Konstanz, Germany facility affected. Anyone heard about other sites? Item | Follow @JohnCFierce

@FierceMedDev: GE ($GE) selects Bionime to launch innovative diabetes solutions. Release | Follow @FierceMedDev

@MarkHFierce: U.K. scientists are adapting a chemo drug to attach to other pills so it can be delivered by capsule or tablet. More | Follow @MarkHFierce

> Takeda to axe 2,800 workers, consolidate R&D in global restructuring. News

> Atlas-backed upstart grabs $21M A round for RNA work. Story

> Columbia shares plunge after FDA staffers blast birth gel app. Article

Drug Delivery News

> Kedem pursues version of Novartis' Gleevec that dissolves under tongue. Item

> 'Smart' nanotech may help treat Type 1 diabetes. More

> Genentech pursues sustained-delivery version of blockbuster eye drug Lucentis. Story

Medical Device News

> Boston Sci boasts of positive study results with Epic stent system. Article

> Ventana, Bayer to collaborate on companion Dx for cancer. News

> Blood test may help detect pancreatic cancer early. Item

> Covidien recalls device linked to 3 deaths during thoracic surgery. News

Biomarkers News

> Researchers inch closer to stomach cancer blood tests. Story

> Qiagen signs diagnostic biomarker deals. Article

> Biomarkers could improve treatment of neuroendocrine tumors. More

> Teams closing in on gene behind form of muscular dystrophy. Item

> Biomarkers making an earache less of a headache. Story

And Finally... Study finds genetic Alzheimer's risk might be mitigated by exercise. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.